BACKGROUND AND OBJECTIVES: Whether the use of tumor necrosis factor antagonists increases the risk of infection remains a subject of open debate. Developing effective strategies of prevention and empirical treatment entails carefully establishing the etiology and prognosis of the infections. PATIENTS AND METHODS: Analysis of the Spanish registry BIOBADASER (Feb-2000 to Jan-2006), a national drug safety registry of patients with rheumatic diseases. RESULTS: 907 episodes of infection occurring in 6,969 patients were analyzed. The infection incidence observed was 53.09 cases/1,000 patients-years (CI 95% 49.69-56.66). The most frequent infections were skin infection (12.18 cases/1,000 patients-yrs), pneumonia (5.97 cases/1,000 patients-yrs), cystitis (3.92 cases/1,000 patients-yrs), tuberculosis (3.51 cases/1,000 patients-yrs) and arthritis (3.76 cases/1,000 patients-yrs). Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa and Salmonella spp. emerged as important pathogens. Varicella zoster virus and Herpes simplex virus caused most cases of viral infections. Mucocutaneous candidiasis accounted for most fungal infections. Mortality was increased in infected patients (log-rank test p<0.0001). Pneumonia, sepsis, tuberculosis, abdominal infection and endocarditis were associated with significant attributable mortality. CONCLUSIONS: A significant number of bacterial, viral and fungal infections occurred in patients with rheumatic diseases treated with TNF antagonists. The information of this study can illuminate clinicians globally on how to address infection in this vulnerable group of patients.
BACKGROUND AND OBJECTIVES: Whether the use of tumor necrosis factor antagonists increases the risk of infection remains a subject of open debate. Developing effective strategies of prevention and empirical treatment entails carefully establishing the etiology and prognosis of the infections. PATIENTS AND METHODS: Analysis of the Spanish registry BIOBADASER (Feb-2000 to Jan-2006), a national drug safety registry of patients with rheumatic diseases. RESULTS: 907 episodes of infection occurring in 6,969 patients were analyzed. The infection incidence observed was 53.09 cases/1,000 patients-years (CI 95% 49.69-56.66). The most frequent infections were skin infection (12.18 cases/1,000 patients-yrs), pneumonia (5.97 cases/1,000 patients-yrs), cystitis (3.92 cases/1,000 patients-yrs), tuberculosis (3.51 cases/1,000 patients-yrs) and arthritis (3.76 cases/1,000 patients-yrs). Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa and Salmonella spp. emerged as important pathogens. Varicella zoster virus and Herpes simplex virus caused most cases of viral infections. Mucocutaneous candidiasis accounted for most fungal infections. Mortality was increased in infectedpatients (log-rank test p<0.0001). Pneumonia, sepsis, tuberculosis, abdominal infection and endocarditis were associated with significant attributable mortality. CONCLUSIONS: A significant number of bacterial, viral and fungal infections occurred in patients with rheumatic diseases treated with TNF antagonists. The information of this study can illuminate clinicians globally on how to address infection in this vulnerable group of patients.
Authors: Raquel S B Oliveira; Ingrid S T Figueiredo; Lyara B N Freitas; Rachel S P Pinheiro; Gerly Anne C Brito; Nylane M N Alencar; Márcio V Ramos; Maria T Ralph; José V Lima-Filho Journal: Inflamm Res Date: 2012-04-10 Impact factor: 4.575
Authors: Roberto Ranza; Maria Celina de la Vega; Ieda Maria Magalhães Laurindo; Marìa Gimena Gómez; David Cezar Titton; Adriana Maria Kakehasi; Alejandro Brigante; Alejandro Benitez; Aline Ranzolin; Amelia Granel; Ana María Cappuccio; Ana Quinteros; André Luiz Shinji Hayata; Andrea Smichowski; Ângela Luzia Branco P Duarte; Barbara Stadler Kahlow; Carolina Sánchez Andia; Claiton Viegas Brenol; Edson Velozo; Eduardo Mussano; Enrique R Soriano; Georges Basile Christopoulos; Geraldo da Rocha Castelar Pinheiro; Gláucio Ricardo Werner de Castro; Gustavo Casado; Hellen Mary da Silveira Carvalho; Ida Elena Exeni; Inês Guimarães da Silveira; Ingrid Petkovic; Ivanio Alves Pereira; Izaias Pereira da Costa; Javier Eduardo Rosa; José Roberto Silva Miranda; Julio Cesar Bertacini de Moraes; Manoel Barros Bertolo; Manuel Buhl; Maria Alícia Lázaro; Maria de Fátima Lobato C da Sauma; Marcelo de Medeiros Pinheiro; Monica Díaz; Mônica Valéria Siqueira Santana de Vechi; Osvaldo Luis Cerda; Pablo Astesana; Pablo Finucci Curi; Paulo Louzada-Jr; Reginaldo Botelho Teodoro; Roberto Acayaba Toledo; Sílvia Papasidero; Valeria Valim; Vander Fernandes; Veronica Saurit; Washington Alves Bianchi; Rogério de Melo Costa Pinto; Miguel Angel Descalzo; Juan Jesus Gomez-Reino Journal: Clin Rheumatol Date: 2019-04-17 Impact factor: 2.980
Authors: Marina Amaral de Ávila Machado; Mariana Michel Barbosa; Alessandra Maciel Almeida; Vânia Eloisa de Araújo; Adriana Maria Kakehasi; Eli Iola Gurgel Andrade; Mariangela Leal Cherchiglia; Francisco de Assis Acurcio Journal: Rheumatol Int Date: 2013-05-18 Impact factor: 2.631
Authors: Isidoro González-Álvaro; Carmen Martínez-Fernández; Benito Dorantes-Calderón; Rosario García-Vicuña; Blanca Hernández-Cruz; Alicia Herrero-Ambrosio; Olatz Ibarra-Barrueta; Emilio Martín-Mola; Emilio Monte-Boquet; Alberto Morell-Baladrón; Raimon Sanmartí; Jesús Sanz-Sanz; Francisco Javier de Toro-Santos; Paloma Vela; José Andrés Román Ivorra; José Luis Poveda-Andrés; Santiago Muñoz-Fernández Journal: Rheumatology (Oxford) Date: 2014-12-19 Impact factor: 7.580